LDN-212854BMP receptor inhibitor,potent and selective CAS# 1432597-26-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1432597-26-6 | SDF | Download SDF |
| PubChem ID | 60182388 | Appearance | Powder |
| Formula | C25H22N6 | M.Wt | 406.48 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 30 mg/mL (73.80 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 5-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | ||
| SMILES | C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=C6C=CC=NC6=CC=C5)N=C3 | ||
| Standard InChIKey | BBDGBGOVJPEFBT-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C25H22N6/c1-3-21(22-4-2-10-27-24(22)5-1)23-16-29-31-17-19(15-28-25(23)31)18-6-8-20(9-7-18)30-13-11-26-12-14-30/h1-10,15-17,26H,11-14H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | LDN-212854 is a potent and selective inhibitor of BMP receptor with IC50 of 1.3 nM for ALK2. | |||||
| Targets | ALK2 | |||||
| IC50 | 1.3 nM | |||||
LDN-212854 Dilution Calculator
LDN-212854 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4601 mL | 12.3007 mL | 24.6015 mL | 49.2029 mL | 61.5036 mL |
| 5 mM | 0.492 mL | 2.4601 mL | 4.9203 mL | 9.8406 mL | 12.3007 mL |
| 10 mM | 0.246 mL | 1.2301 mL | 2.4601 mL | 4.9203 mL | 6.1504 mL |
| 50 mM | 0.0492 mL | 0.246 mL | 0.492 mL | 0.9841 mL | 1.2301 mL |
| 100 mM | 0.0246 mL | 0.123 mL | 0.246 mL | 0.492 mL | 0.615 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
LDN-212854 is a selective inhibitor of bone morphogenetic protein (BMP) signaling with IC50 value of 1.2nM [1].
In the kinase assay, LDN-212854 shows inhibitory activities against caALK2 and caALK5 with IC50 values of 16nM and 2μM, respectively. It demonstrates that LDN-212854 is selective against BMP over TGF-β signaling. Besides that, the inhibition of caALK2 caused by LDN-212854 is 6- and 10-fold more potent than that of caALK1 and caALK3, respectively. In C2C12 cells transfected with BMP receptors, LDN-212854 also exerts preferential inhibition against caALK2. Furthermore, in a transgenic ALK2Q207D model of heterotopic ossification, treatment of LDN-212854 prevents the formation of heterotopic bone and preserves limb range of motion [1].
References:
[1] Mohedas A H, Xing X, Armstrong K A, et al. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS chemical biology, 2013, 8(6): 1291-1302.
- Tin protoporphyrin IX dichloride
Catalog No.:BCC6776
CAS No.:14325-05-4
- Microstegiol
Catalog No.:BCN3157
CAS No.:143246-41-7
- (-)-Isolariciresinol 9'-O-glucoside
Catalog No.:BCN7708
CAS No.:143236-04-8
- (-)-Lyoniresinol 9'-O-glucoside
Catalog No.:BCN7037
CAS No.:143236-02-6
- Z-2-Nal-OH
Catalog No.:BCC3291
CAS No.:143218-10-4
- Dehydroadynerigenin beta-neritrioside
Catalog No.:BCN4706
CAS No.:143212-60-6
- 7-Geranyloxy-5-methoxycoumarin
Catalog No.:BCN5806
CAS No.:1432075-68-7
- (Z)-3-Hydroxy-5-methoxystilbene
Catalog No.:BCN6688
CAS No.:143207-76-5
- 10-O-Acetylisocalamendiol
Catalog No.:BCN7071
CAS No.:1432064-69-1
- 6-O-Acetylcoriatin
Catalog No.:BCN7048
CAS No.:1432063-63-2
- 8-Isomulberrin hydrate
Catalog No.:BCC8789
CAS No.:1432063-35-8
- 3-(3-Hydroxy-3-methylbutanyl)-2,4,6-trihydroxybenzophenone
Catalog No.:BCC8588
CAS No.:1432062-53-7
- AGI-6780
Catalog No.:BCC1331
CAS No.:1432660-47-3
- RA-XI
Catalog No.:BCN3514
CAS No.:143277-27-4
- H-Chg-OH
Catalog No.:BCC3162
CAS No.:14328-51-9
- Ac-YVAD-CHO
Catalog No.:BCC4021
CAS No.:143313-51-3
- UNC 2400
Catalog No.:BCC5625
CAS No.:1433200-49-7
- RS 56812 hydrochloride
Catalog No.:BCC6877
CAS No.:143339-12-2
- SMIP004
Catalog No.:BCC1955
CAS No.:143360-00-3
- Bryostatin 3
Catalog No.:BCC5620
CAS No.:143370-84-7
- Naratriptan
Catalog No.:BCC5053
CAS No.:143388-64-1
- SAR131675
Catalog No.:BCC5097
CAS No.:1433953-83-3
- (Arg)9 peptide
Catalog No.:BCC5336
CAS No.:143413-47-2
- Poriol
Catalog No.:BCN6816
CAS No.:14348-16-4
Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.[Pubmed:28918311]
Bone. 2018 Apr;109:251-258.
Individuals with the rare developmental disorder fibrodysplasia ossificans progressiva (FOP) experience disabling heterotopic ossification caused by a gain of function mutation in the intracellular region of the BMP type I receptor kinase ALK2, encoded by the gene ACVR1. Small molecule BMP type I receptor inhibitors that block this ossification in FOP mouse models have been derived from the pyrazolo[1,5-a]pyrimidine scaffold of dorsomorphin. While the first derivative LDN-193189 exhibited pan inhibition of BMP receptors, the more recent compound LDN-212854 has shown increased selectivity for ALK2. Here we solved the crystal structure of ALK2 in complex with LDN-212854 to define how its binding interactions compare to previously reported BMP and TGFbeta receptor inhibitors. LDN-212854 bound to the kinase hinge region as a typical type I ATP-competitive inhibitor with a single hydrogen bond to ALK2 His286. Specificity arising from the 5-quinoline moiety was associated with a distinct pattern of water-mediated hydrogen bonds involving Lys235 and Glu248 in the inactive conformation favoured by ALK2. The structure of this complex provides a template for the design of future ALK2 inhibitors under development for the treatment of FOP and other related conditions of heterotopic ossification.
